**3. SCIENTIFIC PUBLICATIONS 2010-**

**ORIGINAL RESEARCH ARTICLES (*peer reviewed*)**

60. Ng Tang Fui M, Hoermann R, **Grossmann M**. Effect of testosterone treatment on adipokines and gut hormones in obese men on a hypocaloric diet. **Journal of the Endocrine Society** 2017; 1:302-312.

 *This paper was highlighted in the “Endocrine Daily Briefing” by the US Endocrine Society.*

59. Ng Tang Fui M, Hoermann R, Prendergast LA, Zajac JD, **Grossmann M**. Symptomatic response to testosterone treatment in dieting obese men with low testosterone levels in a randomized, placebo-controlled clinical trial. **International Journal of Obesity** 2017; 41:420-426(Impact Factor: 5.34, Citations: 0)

58. Cheung AS, Gray H, Schache AG, Hoermann R, Lim Joon D, Zajac JD, Pandy MG, **Grossmann M**. Androgen deprivation causes selective deficits in the biomechanical leg muscle function of men during walking: a prospective case-control study. **Journal of Cachexia, Sarcopenia and Muscle** 2017; 8:102-112 (Impact Factor: 7.88, Citations: 0)

 *This paper received an “outstanding abstract award” and an “early investigator award” to Dr. Cheung at ENDO 2016. Dr. Cheung won the 2015 ESA Bryan Hudson award for this work.*

57. Cheung AS, de Rooy C, Hoermann R, Lim Joon D, Zajac JD, Pandy MG, **Grossmann M**. Quality of life decrements in men with prostate cancer undergoing androgen deprivation therapy. **Clinical Endocrinology (Oxf)** 2017; 86:388-394 (Impact Factor: 3.37, Citations: 0)

56. Ng Tang Fui M, Prendergast LA, Dupuis P, Raval M, Strauss BJ, Zajac JD, **Grossmann M**. Effects of Testosterone Treatment on Body Fat and Lean Mass in Obese Men on a Hypocaloric Diet: A Randomized Controlled Trial. **BMC Medicine** 2016; 14:153-164(Impact Factor: 8.001, Citations: 0)

 *This paper was highlighted as “featured research” on the BMC Medicine Homepage, and presented as an oral “late breaking abstract” at ENDO 2016-* *among a total ~2,500 accepted abstracts, only ~20 are accepted in this category. Dr. Ng Tan Fui won the 2016 ESA Bryan Hudson award for this work.*

55. Sinclair M, Gow PJ, **Grossmann M,** Shannon A, Hoermann R Angus PW. Low serum testosterone is associated with adverse outcome in men with cirrhosis independent of the MELD score. **Liver International** 2016; 22:1482-1490(Impact Factor: 5.00, Citations: 0)

54. Sinclair M, **Grossmann M**, Hoermann R, Scodellaro T, Gow P, Angus P. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone: A randomised controlled trial. **Journal of Hepatology** 2016; 65:906-913(Impact Factor: 11.34, Citations: 0)

53. Cheung AS, Hoermann R, Dupuis P, Lim Joon DL, Zajac JD, **Grossmann M**. Relationships between insulin resistance and frailty with body composition and testosterone levels in men undergoing androgen deprivation therapy for prostate cancer. **European Journal of Endocrinology** 2016; 175:229-37(Impact Factor: 4.06, Citations: 0)

52. Cheung AS, de Rooy C, Hoermann R, Gianatti EJ, Hamilton EJ, Roff G, Zajac JD, **Grossmann M**. Correlation of visceral adipose tissue measured by Lunar Prodigy dual x-ray absorptiometry with MRI and CT in older men. **International Journal of Obesity** 2016; 40:1325-1328 (Impact Factor: 5.34, Citations: 0)

51. Sinclair M, Gow PJ, Angus PW, Hoermann R, Handelsman DJ, Wittert GA, Martin S **Grossmann M**. High circulating estrone and low testosterone correlate with adverse clinical outcomes in men with advanced liver disease. **Liver International** 2016; 36:1619-1627 (Impact Factor: 5.00, Citations: 0)

50. Sinclair M, **Grossmann M,** Angus PW, Hey P, Hoermann R, Hey P, Scodellaro T, Gow PJ. Low testosterone is a better predictor of mortality than sarcopenia in men with advanced liver disease. **Journal of Gastroenterology and Hepatology** 2016; 31:661-667 (Impact Factor: 3.50, Citations: 0)

49. Tint AN, Hoermann R, Wong H, Ekinci EI, MacIsaac RJ, Jerums G, Zajac JD, **Grossmann M.** Association of Sex Hormone Binding Globulin and Free Testosterone with Mortality in Men with Type 2 Diabetes Mellitus. **European** **Journal of Endocrinology** 2016; 174:59-68 (Impact Factor: 4.06, Citations: 0)

48. Gianatti EJ, Hoermann R, Lam Q, Dupuis P, Zajac JD, **Grossmann M**. Effect of testosterone treatment on cardiac biomarkers in a randomised controlled trial of men with type 2 diabetes. **Clinical Endocrinology (Oxf)** 2016; 84:55-62 (Impact Factor: 3.37, Citations: 0)

47. Tiu C, Pezaro C, Davis ID, **Grossmann M**, Parente P. Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: A case series and recommendations for management. **Asia Pacif J Clin Oncol** 2015; 11:190-194(Impact Factor: 1.05, Citations: 0)

46. **Grossmann M,** Hoermann R, Wittert G, Yeap BB. Effects of Testosterone Treatment on Glucose Metabolism and Symptoms in Men with Type 2 Diabetes and the Metabolic Syndrome: a Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. **Clinical Endocrinology (Oxf)** 2015; 83:344-351(Impact Factor: 3.37, Citations: 7)

45. Russel N, Delatycki M, **Grossmann M**. Metastatic phaeochromocytoma in a 23-year-old woman with an unclassified variant in the von Hippel Lindau disease gene: How can the pathogenicity of this variant be determined? **Clinical Endocrinology (Oxf)** 2015; 83:15-19 (Impact Factor: 3.37, Citations: 0)

44. **Grossmann M,** Hoermann R, Ng Tang Fui M, Zajac JD, Ierino FL, Roberts MA. Sex Steroids Levels in Chronic Kidney Disease and Kidney Transplant Recipients: Associations with Disease Severity and Prediction of Mortality. **Clinical Endocrinology (Oxf)** 2015; 82:767-775 (Impact Factor: 3.37, Citations: 0)

43. Yeap BB, Alfonso H, Chubb SAP, Gauci R, Byrnes E, Beilby JP, Ebeling PR, Handelsman DJ, Allan CA, **Grossmann M**, Norman PE, Flicker L. Higher serum undercarboxylated osteocalcin and other bone turnover markers are associated with reduced diabetes risk and lower estradiol concentrations in older men. **Journal of Clinical Endocrinology and Metabolism** 2015; 100:63-71 (Impact Factor: 6.43, Citations: 7)

42. **Grossmann M,** Anawalt BD, Wu FCW. Clinical Practice Patterns in the Assessment and Management of Low Testosterone in Men: An International Survey of Endocrinologists. **Clinical Endocrinology (Oxf)** 2015; 82:234-241 Impact Factor: 3.37, Citations: 0)

 *This paper was the subject of an editorial comment in the Journal of Urology*

41. Gianatti EJ, Dupuis P, Hoermann R, Zajac JD, **Grossmann M**.Effect of testosterone treatment on constitutional and sexual in men with type 2 diabetes in a randomized controlled trial. **Journal of Clinical Endocrinology and Metabolism** 2014; 99:3812-3828 (Impact Factor: 6.43, Citations: 9)

 *This paper was the subject of an editorial in the Asian Journal of Andrology.*

40. Cheung AS, Baqar S, Sia R, Hoermann R, Iuliano-Burns R, Vu TDT, Chiang C, Hamilton EJ, Gianatti EJ, Seeman E, Zajac JD, **Grossmann M**.Testosterone levels increase in association with recovery from acute fracture in men. **Osteoporosis International** 2014; 25: 2027-2033 (Impact Factor: 4.04, Citations: 0)

39. Gianatti EJ, Dupuis P, Hoermann R, Strauss BJ, Wentworth JM, Zajac JD, **Grossmann M**.Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial. **Diabetes Care** 2014; 37:2098-2107 (Impact Factor: 8.1, Citations: 13)

*Dr. Gianatti won the 2013 ESA Bryan Hudson award for this work.*

38. Sinclair M, Angus PW, Gow PJ, Hoermann R, Mogilevski T, **Grossmann M**.Low serum testosterone levels pre-liver transplantation are associated with reduced rates of early acute allograft rejection in men. **Transplantation** 2014; 98:788-792 (Impact Factor: 3.78, Citations: 0)

37. Ng Tang Fui M, Hoermann R, Gianatti EJ, Zajac JD, **Grossmann M**.Obesity and age as dominant correlates of testosterone in men irrespective of diabetes status. **Andrology** 2013; 1: 906-912 (Impact Factor: 3.29, Citations: 8)

36. Cheung AS, Pattison D, Bretherton I, Hoermann R, Lim Joon D, Ho E, Jenkins T, Hamilton EJ, Bate K, Chan I, Zajac JD, **Grossmann M**.Cardiovascular risk and bone loss in men undergoing androgen deprivation therapy for prostate cancer: implementation of standardized management guidelines. **Andrology** 2013; 1: 583-589 (Impact Factor: 3.29, Citations: 20)

35. **Grossmann M,** Hoermann R, Francis C, Hamilton EJ, Tint A, Kaitu’u-Lino T, Kuswanto K, Lappas M, Sikaris K, Zajac JD, Permezel M, Tong S. Measuring thyroid peroxidase antibodies on the day nulliparous women present for management of miscarriage: a descriptive cohort study. **Reproductive Biology and Endocrinology** 2013; 11: 40-45 (Impact Factor: 2.05, Citations: 0)

34. Lorenzo FR, Chunzhang Yang C, Ng Tang Fui M, Vankayalapati H, Zhuang Z, Huynh T, **Grossmann M,** Pacak K, Prchal JT.A Novel *EPAS1/HIF2A* germline mutation in a congenital polycythemia with paraganglioma. **Journal of Molecular Medicine**2013;91: 507-516 (Impact Factor: 4.67, Citations: 57)

33. **Grossmann M,** Hoermann R, Gani L, Chan I., Cheung A, Gow PJ, Li A, Zajac JD, Angus P. Low testosterone levels as independent predictor of mortality in men with chronic liver disease. **Clinical Endocrinology (Oxf)** 2012; 77: 323-328 (Impact Factor: 3.37, Citations: 9)

32. Verma S, Lewis D, Warne G, **Grossmann M**. An X-traordinary stroke. **The Lancet** 2011;377: 1288(Impact Factor: 28.64, Citations: 2)

31. Hamilton EJ, Gianatti EJ, Strauss BJ, Wentworth J, Lim-Joon D, Bolton D, Zajac JD, **Grossmann M**. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. **Clinical Endocrinology (Oxf)** 2011; 74: 377-383 (Impact Factor: 3.37, Citations: 71)

30. Hamilton EJ, Ghasem-Zadeh A, Gianatti EJ, Lim-Joon D, Bolton, D, Zebaze R, Seeman E, Zajac JD, **Grossmann, M**. Structural Decay of Bone Microarchitecture in Men with Prostate Cancer treated with Androgen Deprivation Therapy. **Journal of Clinical Endocrinology and Metabolism** 2010; 95: E456-463 (Impact Factor: 6.43, Citations: 36)

29. Yip G, Ekinci E, Lee ST, Jerums G, **Grossmann M.** Carbimazole-induced agranulocytosis: does ANCA have a role? **Internal Medicine Journal** 2010; 40: 400-403.(Impact Factor: 1.57, Citations: 8)

**REVIEW ARTICLES (*peer reviewed*)**

27. Cheung AS, **Grossmann M**. Physiological Basis behind Ergogenic Effects of Anabolic Androgens. **Molecular and Cellular Endocrinology** 2017; *in press* (Impact Factor: 3.61, Citations: 0)

26. **Grossmann M**, Matsumoto AM. A perspective on middle-aged and older men with functional hypogonadism: focus on holistic management. **Journal of Clinical Endocrinology and Metabolism** 2017; *in press* (accepted 14/1/17) (Impact Factor: 6.43, Citations: 0)

 *This perspective was highlighted as an “Editors Choice” article in the March 2017 edition of the JCEM.*

25. Ramchand SK,Lim E, **Grossmann M**. Adjuvant endocrine therapy in women with oestrogen-receptor-positive breast cancer: How should the skeletal and vascular side effects be assessed and managed? **Clinical Endocrinology (Oxf).** 2016; 85, 689–693(Impact Factor: 3.37, Citations: 0)

24. Sinclair M,Gow PJ, **Grossmann M**,Angus PW. Sarcopenia in cirrhosis – aetiology, implications and potential therapeutic interventions. **Alimentary Pharmacology & Therapeutics.** 2016; 43:765-77(Impact Factor: 5.73, Citations: 0)

23. de Rooy C, **Grossmann M**, Zajac JD, Cheung AS. Targeting muscle signaling pathways to minimize adverse effects of androgen deprivation. **Endocrine-Related Cancer** 2016; 23:R15-26 (Impact Factor: 5.44, Citations: 0)

22.Davey RA, **Grossmann M**.Androgen receptor structure, function and biology: from bench to bedside. **The Clinical Biochemist Reviews** 2016; 37:3-15

21.Sinclair M, **Grossmann M**,Gow PJ, Angus PW. Testosterone in men with advanced liver disease: abnormalities and implications. **Journal of Gastroenterology and Hepatology** 2015; 30:244-251 (Impact Factor: 3.33)

20. Cheung AS, Zajac JD, **Grossmann M**. Muscle and bone effects of androgen deprivation therapy; current and emerging therapies. **Endocrine-Related Cancer** 2014; 21:R371-R394 (Impact Factor: 5.44, Citations: 0)

 *This paper won a top cited Author Award in 2016.*

19. **Grossmann M**. Testosterone and glucose metabolism in men: current concepts and controversies. **Journal of Endocrinology** 2014; 220: R37-55 (Impact Factor: 4.06, Citations: 13)

 *This paper won a top cited Author Award in 2016.*

18.Ng Tang Fui M, Dupuis P, **Grossmann M**. Lowered testosterone in male obesity: mechanisms, morbidity and management. **Asian Journal of Andrology** 2014; 16: 223-231(Impact Factor: 2.53, Citations: 17)

 *This paper received the 2016 “AJA Outstanding Paper Award” (in total 20 papers received this award).*

17. **Grossmann M**, Cheung AS, Zajac JD. Androgens and prostate cancer; pathogenesis and deprivation therapy. **Best Practice & Research Clinical Endocrinology & Metabolism** 2013; 27: 603-616 (Impact Factor: 4.59, Citations: 23)

16. **Grossmann M** & Wittert G. Androgens, diabetes and prostate cancer. **Endocrine-Related Cancer** 2012; 5: F47-F62 (Impact Factor: 5.44, Citations: 15)

15. **Grossmann M** & Zajac JD. Hematological changes during androgen deprivation. **Asian Journal of Andrology** 2012; 14: 187-192 (Impact Factor: 2.53, Citations: 19)

14. **Grossmann M**. Low Testosterone in men with diabetes: significance and treatment. **Journal of Clinical Endocrinology and Metabolism** 2011; 96: 2341-2353 (Impact Factor: 6.43, Citations: 126)

13. **Grossmann M**, Zajac JD. Androgen deprivation therapy in men with prostate cancer: How should the side effects be monitored and treated? **Clinical Endocrinology (Oxf)** 2011; 74: 289-293 (Impact Factor: 3.37, Citations: 38)

12. **Grossmann, M**. Diagnosis and treatment of hypogonadism in older men. **Asian Journal of Andrology** 2010; 12: 783-786 (Impact Factor: 2.53, Citations: 7)

11. **Grossmann M**, Gianatti EJ, Zajac JD. Testosterone and Type 2 Diabetes. **Current Opinion in Endocrinology, Diabetes and Obesity.** 2010; 17: 247-256 (Impact Factor: 3.62, Citations: 68)

**POSITION STATEMENTS (*peer reviewed*)**

3. Yeap BB, **Grossmann M,** McLachlan RI, Handelsman DJ, Wittert GA, Conway AJ, Stuckey BGA, Lording DW, Allan CA, Zajac JD, Burger HG. Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations. **Medical Journal of Australia** 2016, 205:228-231 (Impact Factor: 2.89, Citations: 0)

2. Yeap BB, **Grossmann M,** McLachlan RI, Handelsman DJ, Wittert GA, Conway AJ, Stuckey BGA, Lording DW, Allan CA, Zajac JD, Burger HG. Endocrine Society of Australia position statement on male hypogonadism (part 1): assessment and indications for testosterone therapy. **Medical Journal of Australia** 2016, 205:173-178(Impact Factor: 2.89, Citations: 0)

1. **Grossmann M,** Hamilton EJ, Gilfillan C, Bolton D, Lim Joon D, Zajac, JD. Bone and Metabolic Health in Patients with Prostate Cancer Receiving Androgen Deprivation Therapy- Management Guidelines on behalf of the Endocrine Society of Australia, the Australian and New Zealand Bone and Mineral Society, and the Urological Society of Australia and New Zealand. **Medical Journal of Australia** 2011; 194: 301-306 (Impact Factor: 2.89, Citations: 43)

**INVITED EDITORIALS AND COMMENTARIES (*peer reviewed*)**

6. Nolan B, **Grossmann M.** Testosterone treatment in older men: glass half empty or half full? **Asian Journal of Andrology** 2017; *in press* (Impact Factor: 2.53)

5. Russell N, **Grossmann M.** Plasma miRNA expression profile in the diagnosis of late-onset hypogonadism. **Asian Journal of Andrology** 2016; 18:713-715(Impact Factor: 2.53)

4. **Grossmann M**.Myostatin Inhibition: A New Treatment for Androgen Deprivation-Induced Sarcopenia? **Journal of Clinical Endocrinology and Metabolism** 2014; 99: 3265-3268 (Impact Factor: 6.43, Citations: 0)

3. **Grossmann M,** Wu FCW.Male androgen deficiency: a multisystem disorder. **Asian Journal of Andrology** 2014; 16: 159-160 (Impact Factor: 2.53, Citations: 0)

2. Ng Tang Fui M, **Grossmann M.** Androgen deprivation therapy in men with metastatic prostate cancer: less may not necessarily be more. **Asian Journal of Andrology** 2013; 15: 445-446 (Impact Factor: 2.53)

1. Cheung AS, **Grossmann M.** Cox-2 inhibitors in prostrate cancer treatment. **Asian Journal of Andrology** 2012; 14: 518-519 (Impact Factor: 2.53)

**RESEARCH COMMUNICATIONS (*peer reviewed*)**

2. Ng Tang Fui M, **Grossmann M**. Clinical Picture: Hypogonadism from androgen deprivation therapy in identical twins. **The Lancet** 2016;388: 2653 (Impact Factor: 28.64, Citations: 0)

1. **Grossmann M**, Cheung AS. Impact of Androgen Deprivation Therapy on High-Level Physical Performance. **European Urology** 2016; 69: 1161-62 (Impact Factor: 13.93, Citations: 0)

**LETTERS (*scientific correspondence*)**

4. **Grossmann M**. Danazol and telomerase gene activation. **New England Journal of Medicine** 2016; *in press* (Impact Factor: 53.29, Citations: 0)

5. Gianatti EJ, Hoermann R, **Grossmann M**.Response:Effect of testosterone treatment on glucose metabolism in men with type 2 diabetes: a randomized controlled trial. **Diabetes Care** 2014; 37:e269 (Impact Factor: 8.1, Citations: 0)

4. **Grossmann M**. Mutant Prolactin Receptor and Familial Hyperprolactinemia. **New England Journal of Medicine** 2014; 370: 976-977 (Impact Factor: 53.29, Citations: 7)

3. Sinclair M, Angus P, **Grossmann M,** Gow P. Muscle Mass and Mortality in Chronic Liver Disease: the Impact of Testosterone. **Liver Transplantation** 2014; 20: 504-505. (Impact Factor: 3.94)

2. Hoermann R, **Grossmann M**. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. **New England Journal of Medicine** 2013; 369: 674. (Impact Factor: 53.29)

1. Sinclair M, **Grossmann M,** Gow PJ, Angus P. Higher Serum Testosterone Is Associated With Increased Risk of Advanced Hepatitis C–Related Liver Disease in Males. **Hepatology** 2012; 56: 2007 (Impact Factor: 10.88)

**BOOK CHAPTERS**

6. **Grossmann M** Utility and Limitations of Testosterone Measurements. In Hohl Alexandre (*ed*), Testosterone from Basic to Clinical Aspects (1st edition) Springer International Publishing Switzerland 2017

5. **Grossmann M** Testosterone Therapy: Optimizing Benefits and Minimizing Risks. Meet-The-Professor Book 2015. **ENDO**, San Diego, CA, USA.

4. **Grossmann M** Low testosterone: when to treat. Meet-The-Professor Book 2014. **ENDO**/ICE, Chicago, ILL, USA.

3. **Grossmann M** Low testosterone in men with metabolic disorders. Meet-The-Professor Book 2013. **ENDO**, San Francisco, CA, USA.

2. **Grossmann M**, Zajac JD. Management of side effects of androgen deprivation therapy. **Endocrinology and Metabolism Clinics of North America** 2011; 40: 655-671 (Impact Factor: 3.80, Citations: 30)

**EDUCATIONAL PUBLICATIONS**

12. Nolan BJ, **Grossmann M**. Bone health and prostate cancer. **Endocrinology Today** 2017; 6:35-37.

11. Ramchand S, **Grossmann M**. Oestrogen deprivation and breast cancer **Australian Doctor** 2016; 7 October:21-28

10. Russell N, **Grossmann M**. Therapy Update: Water Balance Part 2: Treatment of hyponatraemia. **Australian Doctor** 2016; 5 August:31-34

9. Russell N, **Grossmann M**. Therapy Update: Water Balance Part 1: Evaluation of hyponatraemia. **Australian Doctor** 2016; 29 July:31-34

8. **Grossmann M**. How To Treat: Low testosterone. Part 2: Management. **Australian Doctor** 2015; 3 July:21-28; reprinted in the **Medical Observer**, May 2017

7. **Grossmann M**. How To Treat: Low testosterone. Part 1: Diagnosis. **Australian Doctor** 2015; 26 June:23-30; reprinted in the **Medical Observer**, May 2017

6. Ramchand S, **Grossmann M**. Role of Testosterone in Men with Type 2 Diabetes Mellitus. **Endocrinology Today** 2015; 4:35-38.

5. Ramchand S, **Grossmann M**. Testosterone and glucose metabolism: implications of low testosterone in men with type 2 diabetes and its clinical management. **Diabetes Management** **Journal** 2015; 46:28-31

4. Chan I, Ng Tang Fui M, Zajac JD, Grossmann M. Male androgen disorders: an update. **Australian Family Physician** 2014; 43:227-282.

3. So M, MacIsaac R, **Grossmann M**. Hypothyroidism: investigations and management. **Australian Family Physician** 2012; 8: 556-562

2. Ng Tang Fui M, **Grossmann M**. Should universal screening of testosterone be performed in diabetic male patients? **Diabetes Management** **Journal** 2012; 38:22-23